CSP #2026 - Beta Blocker Dialyzability on Cardiovascular Outcomes

Recruiting now · Phase 3

Conditions studied: End-Stage Kidney Disease, End-Stage Renal Disease

In brief

The investigators aim to determine, using a point-of-care randomized controlled trial design, if hemodialysis patients, who are randomized to metoprolol succinate (a dialyzable, beta-1 selective beta blocker), have an improved cardiovascular outcome compared to those randomized to carvedilol (a non-dialyzable, non-selective beta blocker with alpha-1 antagonist properties). The investigators will also examine intervention practices to identify components that best support engagement and sustainability.

Key facts

Study ID
NCT05931276
Run by
VA Office of Research and Development
People needed
2540
Starts
2024-05-22
Expected to finish
2028-12-31
Last updated by the study team
2026-01-09

Who can join

Age: 18 and older. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

You may not qualify if…

Where it is running

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.